Skip to main content

Table 2 The administration of anticancer agents and supportive therapy agents, and the development of TLS by type of therapy

From: Bortezomib administration is a risk factor associated with the development of tumor lysis syndrome in male patients with multiple myeloma: a retrospective study

   Total (n = 210) Developed TLS
(n = 17)
No TLS (n = 193) P-value
(A) Administration of anticancer agents andsupportive therapy agents for TLS prophylaxis
Anti-cancer agents
  Number of therapy cycles Median (Range)    
  3 (1–59) 3 (1–11) 3 (1–59) 0.887
  Duration of treatment (days) Mean ± SD     
  150.6 ± 177.4 143.0 ± 119.8 151.3 ± 181.9 0.854
  Dose reduction during treatment No. (%)     
  115 (54.8) 13 (76.5) 102 (52.8) 0.076
Antihyperuricemic agents
  Yes a No. (%) 73 (34.8) 7 (41.2) 66 (34.2) 0.600
   Allopurinol/ febuxostat   72 7 65  
   Rasburicase   1 0 1  
Hydration
  Yes b No. (%) 89 (42.4) 8 (47.1) 81 (42.0) 0.880
Urine alkalization
  Yes c No. (%) 131 (62.4) 12 (80.0) 119 (77.8) 1.000
(B) The development of TLS by type of therapy
 Bortezomib-containing therapy No. (%) 130 (61.9) 14 (82.4) 116 (60.1) 0.115 e
  Intravenously   29 2 27  
  Subcutaneously   101 12 89  
Therapy without Bortezomib d   80 (38.1) 3 (17.6) 77 (39.9)  
  1. P-values were determined by Mann-Whitney U-test for number of therapy cycles, Fisher’s exact test for categorical variables, and Student’s t-test for continuous variables
  2. SD Standard deviation, TLS Tumor lysis syndrome
  3. aDefined as being administered prior to the commencement of the primary treatment for multiple myeloma
  4. bDefined as the average volume over 1000 mL / day for eight days (from one day before to 7 days after the initiation of multiple myeloma primary treatment)
  5. cDefined as being administered sodium bicarbonate agent before the initiation of multiple myeloma primary treatment
  6. dTherapies that did not include bortezomib
  7. eComparison between bortezomib-containing therapy and therapy without bortezomib
\